Drugs Made In America Acquisition Corp
DMAA
23 hedge funds and large institutions have $125M invested in Drugs Made In America Acquisition Corp in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 15 reducing their positions, and 17 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
18.95% less ownership
Funds ownership: 68.23% → 49.28% (-19%)
41% less funds holding
Funds holding: 39 → 23 (-16)
47% less capital invested
Capital invested by funds: $237M → $125M (-$112M)
80% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 15
94% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSC
Logan Stone Capital
Chicago,
Illinois
|
+$1.16M |
| 2 |
MSU
Mizuho Securities USA
New York
|
+$737K |
| 3 |
CS
Clear Street
New York
|
+$301K |
| 4 |
JP Morgan Chase
New York
|
+$106 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
-$15.4M |
| 2 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
-$11.5M |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$7.64M |
| 4 |
D.E. Shaw & Co
New York
|
-$7.25M |
| 5 |
GCL
Glazer Capital LLC
New York
|
-$7.18M |
DMAA Hedge Fund Activity: Q2 2026 in Review
23 of the 8,345 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition Corp (DMAA) for Q2 2026, worth a combined $125M — down 47% from $237M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of DMAA and 1 opened new positions — a net loss of 16 holders — while 15 trimmed existing stakes and 3 added.
The largest buyer was Logan Stone Capital, opening a new position worth an estimated $1.16M. The largest seller was First Trust Capital Management, cutting an estimated $15.4M.
- 23 institutional investors held Drugs Made In America Acquisition Corp (DMAA) as of Q2 2026, down from 39 in Q1 2026.
- Funds reported $125M of Drugs Made In America Acquisition Corp stock for Q2 2026, down 47% quarter-over-quarter.
- 1 fund opened new Drugs Made In America Acquisition Corp positions in Q2 2026 and 17 closed out, a net change of -16 holders.
- The largest Drugs Made In America Acquisition Corp buyer in Q2 2026 was Logan Stone Capital, an estimated $1.16M added.
- The largest Drugs Made In America Acquisition Corp seller in Q2 2026 was First Trust Capital Management, an estimated $15.4M sold.
Based on aggregated 13F filings for Q2 2026.